Amber Ilyas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amber Ilyas has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Zehra Hashim
Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi, 75270, Pakistan.
3 shared publications - Alex von Kriegsheim
Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh
2 shared publications - Farha Idrees
Dr. Ziauddin Hospital, Karachi, 74700, Pakistan
2 shared publications - Nida Syed
Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi, 75270, Pakistan
2 shared publications - Shamshad Zarina
Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi, Pakistan
2 shared publications - Syeda Abiha Zehra Jaffari
Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi, 75270, Pakistan
2 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
UBB as an early-stage potential biomarker for breast cancer via modulation of the ubiquitination pathway
Breast cancer ranks second leading cause of cancer related mortality worldwide, emphasizing the need of early diagnosis to improve therapeutic outcomes and disease-free survival. Ubiquitin, a highly conserved protein binds to target proteins to alter their functions, stability, and signaling activity. Multiple ubiquitination forms polyubiquitin chains, which may lead to proteasomal degradation and influence major signaling pathways. In this study, we demonstrate the potential of polyubiquitin B (UBB) as a promising biomarker for early stage breast cancer. We investigated the expression of UBB and ubiquitination pathway associated proteins in female breast cancer patients. Label free quantitative proteomic analysis revealed differentially expressed proteins, followed by network based analysis that identified key hub proteins. Furthermore, quantitative gene expression of hub proteins and other regulators of ubiquitination, demonstrated their alterations in breast cancer. Elevated expression of UBB was validated using competitive ELISA. Molecular docking between ubiquitin-specific protease 2 (USP2) and ubiquitin (PDB ID: 3NHE) in the presence of ML364 highlights the USP2 as potential drug target. Our findings establish a critical role for UBB and ubiquitination pathway proteins in breast carcinogenesis and disease progression. This study may provide valuable insights into early breast cancer diagnosis and supports the development of targeted therapeutic strategies.
- 12 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessUBB as an early-stage potential biomarker for breast cancer via modulation of the ubiquitination pathway
Breast cancer ranks second leading cause of cancer related mortality worldwide, emphasizing the need of early diagnosis to improve therapeutic outcomes and disease-free survival. Ubiquitin, a highly conserved protein binds to target proteins to alter their functions, stability, and signaling activity. Multiple ubiquitination forms polyubiquitin chains, which may lead to proteasomal degradation and influence major signaling pathways. In this study, we demonstrate the potential of polyubiquitin B (UBB) as a promising biomarker for early stage breast cancer. We investigated the expression of UBB and ubiquitination pathway associated proteins in female breast cancer patients. Label free quantitative proteomic analysis revealed differentially expressed proteins, followed by network based analysis that identified key hub proteins. Furthermore, quantitative gene expression of hub proteins and other regulators of ubiquitination, demonstrated their alterations in breast cancer. Elevated expression of UBB was validated using competitive ELISA. Molecular docking between ubiquitin-specific protease 2 (USP2) and ubiquitin (PDB ID: 3NHE) in the presence of ML364 highlights the USP2 as potential drug target. Our findings establish a critical role for UBB and ubiquitination pathway proteins in breast carcinogenesis and disease progression. This study may provide valuable insights into early breast cancer diagnosis and supports the development of targeted therapeutic strategies.
- 2 February 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (4) , 2793-2805
miRNA-1231 Regulated EGFR Signaling: A Potential Therapeutic Target for Hepatocellular Carcinoma
- 2 February 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (4) , 2793-2805
miRNA-1231 Regulated EGFR Signaling: A Potential Therapeutic Target for Hepatocellular Carcinoma
- Open Access
- 30 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Gene expression analysis of diabetic foot ulcers reveals the potential impact of Levofloxacin on wound healing
Chronic nonhealing wounds in diabetic patients represent a significant and persistent clinical challenge, contributing to the increased morbidity and mortality of patients with diabetes worldwide. The selection of an appropriate treatment strategy is crucial for mitigating these challenges and enhancing clinical outcomes. While antibiotics are commonly employed to manage infections associated with diabetic foot ulcers (DFUs), their over prescription and prolong use remains a contentious issue. There is evidence linking antibiotics to the induction of oxidative stress, which aggravates the already disrupted redox balance in diabetic patients, thereby worsening their cellular functions. However, the molecular mechanisms and effects of these antibiotics on the expression profiles of genes have not been studied before. Therefore, the present study aimed to analyze alterations in the expression of key wound healing-related genes, such as TGFΒ-1, NFE2L2 ( also called Nrf2 ), HMOX1, and MMP-9, following Levofloxacin use in patients with DFUs. Biopsy samples were collected from a cohort of 30 participants and categorized into three groups: DFUs treated with antibiotics (DFU + Ab), DFUs without antibiotics (DFU-Ab), and a control group (C). The gene expression levels were evaluated via reverse transcriptase quantitative PCR (RT‒qPCR). Our findings revealed a significant (p < 0.05) increase in the expression of TGFβ-1, HMOX-1, NFE2L2 , and MMP-9 in the presence of antibiotic (Levofloxacin). The increase in the expression of these genes suggests that antibiotics may induce oxidative stress, leading to biological changes through altering the expression of genes involved in oxidative stress and the inflammatory pathway, thus impacting the wound healing process.
- 30 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessGene expression analysis of diabetic foot ulcers reveals the potential impact of Levofloxacin on wound healing
Chronic nonhealing wounds in diabetic patients represent a significant and persistent clinical challenge, contributing to the increased morbidity and mortality of patients with diabetes worldwide. The selection of an appropriate treatment strategy is crucial for mitigating these challenges and enhancing clinical outcomes. While antibiotics are commonly employed to manage infections associated with diabetic foot ulcers (DFUs), their over prescription and prolong use remains a contentious issue. There is evidence linking antibiotics to the induction of oxidative stress, which aggravates the already disrupted redox balance in diabetic patients, thereby worsening their cellular functions. However, the molecular mechanisms and effects of these antibiotics on the expression profiles of genes have not been studied before. Therefore, the present study aimed to analyze alterations in the expression of key wound healing-related genes, such as TGFΒ-1, NFE2L2 ( also called Nrf2 ), HMOX1, and MMP-9, following Levofloxacin use in patients with DFUs. Biopsy samples were collected from a cohort of 30 participants and categorized into three groups: DFUs treated with antibiotics (DFU + Ab), DFUs without antibiotics (DFU-Ab), and a control group (C). The gene expression levels were evaluated via reverse transcriptase quantitative PCR (RT‒qPCR). Our findings revealed a significant (p < 0.05) increase in the expression of TGFβ-1, HMOX-1, NFE2L2 , and MMP-9 in the presence of antibiotic (Levofloxacin). The increase in the expression of these genes suggests that antibiotics may induce oxidative stress, leading to biological changes through altering the expression of genes involved in oxidative stress and the inflammatory pathway, thus impacting the wound healing process.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 26 (10) , 727-737
GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer
Introduction: Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer. Methods: Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry. Results: The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues. Discussion: Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage. Conclusion: It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 26 (10) , 727-737
GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer
Introduction: Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer. Methods: Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry. Results: The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues. Discussion: Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage. Conclusion: It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.
- Open Access
- 14 May 2025
- Published by SAGE Publications in Cancer Informatics
- Vol. 24
Identification of Potential Hub Proteins as Theragnostic Targets in Hepatocellular Carcinoma through Comprehensive Quantitative Tissue Proteomics Analysis
Objective: Hepatocellular carcinoma (HCC) is the most common primary liver cancer mainly caused by hepatitis viral infection. Early stage diagnosis is still challenging due to its asymptomatic behavior so there is an urgent need for effective biomarkers. This study aimed to identify effective diagnostic biomarker or therapeutic target for HCC. Method: Label-free quantitative mass spectrometry was performed to analyze protein expression in HCC and control tissues. Protein-protein interaction (PPI) analysis was done using the STRING database and hub proteins were identified by Cytohubba. The survival analysis and expressions profiling of hub proteins were performed by using GEPIA. Functional and pathway enrichment analysis were carried out using Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG). Results: A total of 1539 proteins were identified, of which 116 were differentially expressed proteins (DEPs). PPI network analysis revealed 10 hub proteins; EGFR, GAPDH, HSP90AA1, MMP9, PTPRC, CD44, ANXA5, PECAM1, MMP2, and CDK1. Among these, GAPDH, MMP9, ANXA5, HSP90AA1, and CDK1 were significantly associated with low survival rate ( p ⩽ .05). Moreover, MMP9 and CDK1 were showed significantly increased expression in tumor tissues as compared to control ( p ⩽ .05). The GO analysis based on biological process, cellular components and molecular function indicated that DEPs were enriched in stress response, vesicle and extracellular space, protein binding and enzyme activity. The KEGG pathway analysis showed that the thyroid hormone synthesis pathway is the most enriched. Conclusion: The hub proteins GAPDH, HSP90AA1, MMP9, ANXA5, and CDK1 demonstrated significant prognostic potential, could be used as promising theragnostic biomarkers for HCC.
- 14 May 2025
- Published by SAGE Publications in Cancer Informatics
- Vol. 24
Open AccessIdentification of Potential Hub Proteins as Theragnostic Targets in Hepatocellular Carcinoma through Comprehensive Quantitative Tissue Proteomics Analysis
Objective: Hepatocellular carcinoma (HCC) is the most common primary liver cancer mainly caused by hepatitis viral infection. Early stage diagnosis is still challenging due to its asymptomatic behavior so there is an urgent need for effective biomarkers. This study aimed to identify effective diagnostic biomarker or therapeutic target for HCC. Method: Label-free quantitative mass spectrometry was performed to analyze protein expression in HCC and control tissues. Protein-protein interaction (PPI) analysis was done using the STRING database and hub proteins were identified by Cytohubba. The survival analysis and expressions profiling of hub proteins were performed by using GEPIA. Functional and pathway enrichment analysis were carried out using Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG). Results: A total of 1539 proteins were identified, of which 116 were differentially expressed proteins (DEPs). PPI network analysis revealed 10 hub proteins; EGFR, GAPDH, HSP90AA1, MMP9, PTPRC, CD44, ANXA5, PECAM1, MMP2, and CDK1. Among these, GAPDH, MMP9, ANXA5, HSP90AA1, and CDK1 were significantly associated with low survival rate ( p ⩽ .05). Moreover, MMP9 and CDK1 were showed significantly increased expression in tumor tissues as compared to control ( p ⩽ .05). The GO analysis based on biological process, cellular components and molecular function indicated that DEPs were enriched in stress response, vesicle and extracellular space, protein binding and enzyme activity. The KEGG pathway analysis showed that the thyroid hormone synthesis pathway is the most enriched. Conclusion: The hub proteins GAPDH, HSP90AA1, MMP9, ANXA5, and CDK1 demonstrated significant prognostic potential, could be used as promising theragnostic biomarkers for HCC.
- 20 July 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (4) , 2110-2121
Differential Protein Expression in Response to Varlitinib Treatment in Oral Cancer Cell Line: an In Vitro Therapeutic Approach
Epidermal growth factor receptor (EGFR) is the most frequently overexpressed receptor histologically exhibited by oral squamous cell carcinoma (OSCC) patients. Aberrated EGFR signaling may lead to recurrence and metastasis, thus laying the foundation of targeted therapy. Deactivating EGFR is likely to prevent downstream signaling thus resulting in apoptosis. Tyrosine kinase inhibitors (TKIs) have come into play to revert aggressiveness of OSCC. We exploited comparative proteomic analyses based on anti‐EGFR potential of varlitinib, using cellular proteomes from treated and untreated groups of oral cancer cells to identify protein players functional during oral carcinogenesis. Following separation by two-dimensional electrophoresis, differentially expressed cellular proteins (varlitinib-treated and untreated cells) were analyzed and later identified using QTOF mass spectrometer. In silico analysis for protein–protein interaction was carried out using STRING. Six differentially expressed proteins were identified as binding immunoglobulin protein (BiP), heat shock protein 7 C (HSP7C), protein disulfide isomerase 1 A (PDIA1), vimentin (VIME), keratin type I cytoskeletal 14 (K1C14), and β-Actin (ACTB). Relative expression of five proteins was found to be downregulated upon varlitinib treatment, whereas only K1C14 was upregulated in treated cells compared to control. Protein network analysis depicts the interaction between BiP, PDIA1, VIME, etc. indicating their role in oral carcinogenesis. Oral cancer cells show proteome shift based on varlitinib treatment compared to corresponding controls. Our data suggest candidature of varlitinib as a potent therapeutic agent and BiP, PDIA1, HSP7C, VIME, and β-Actin as complementary/prognostic markers of OSCC.
- 20 July 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (4) , 2110-2121
Differential Protein Expression in Response to Varlitinib Treatment in Oral Cancer Cell Line: an In Vitro Therapeutic Approach
Epidermal growth factor receptor (EGFR) is the most frequently overexpressed receptor histologically exhibited by oral squamous cell carcinoma (OSCC) patients. Aberrated EGFR signaling may lead to recurrence and metastasis, thus laying the foundation of targeted therapy. Deactivating EGFR is likely to prevent downstream signaling thus resulting in apoptosis. Tyrosine kinase inhibitors (TKIs) have come into play to revert aggressiveness of OSCC. We exploited comparative proteomic analyses based on anti‐EGFR potential of varlitinib, using cellular proteomes from treated and untreated groups of oral cancer cells to identify protein players functional during oral carcinogenesis. Following separation by two-dimensional electrophoresis, differentially expressed cellular proteins (varlitinib-treated and untreated cells) were analyzed and later identified using QTOF mass spectrometer. In silico analysis for protein–protein interaction was carried out using STRING. Six differentially expressed proteins were identified as binding immunoglobulin protein (BiP), heat shock protein 7 C (HSP7C), protein disulfide isomerase 1 A (PDIA1), vimentin (VIME), keratin type I cytoskeletal 14 (K1C14), and β-Actin (ACTB). Relative expression of five proteins was found to be downregulated upon varlitinib treatment, whereas only K1C14 was upregulated in treated cells compared to control. Protein network analysis depicts the interaction between BiP, PDIA1, VIME, etc. indicating their role in oral carcinogenesis. Oral cancer cells show proteome shift based on varlitinib treatment compared to corresponding controls. Our data suggest candidature of varlitinib as a potent therapeutic agent and BiP, PDIA1, HSP7C, VIME, and β-Actin as complementary/prognostic markers of OSCC.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 30 (7) , 587-596
Polymorphic Variants of ASS1 Gene Related to Arginine Metabolism and the Risk of HCC
Background: Hepatocellular carcinoma is a primary liver cancer and 6th most common cancer globally. Inefficient diagnostic strategies and the limited availability of treatments are the foremost reasons. Variable factors directly impact the disease burden, among them, molecular alterations have been found to play a significant role. In liver, argininosuccinate synthase-1 is a center of arginine metabolism and rate limiting enzyme of urea cycle. It also triggers multiple mechanisms that lead to HCC pathogenesis. Objectives: The aim of this study is to analyze the ASS1 gene expression, its polymorphic genotype and microsatellite instability among HCC patients from our Pakistani population. Method: Blood samples were collected from disease and healthy control individuals. Allele-Specific PCR was performed for SNP analysis. MSI of tri and tetra nucleotide repeats were analyzed by PCR. The differential expression of ASS1 gene was also investigated. Furthermore, the reactome database and STRING software were utilized for finding correlations between ASS1 gene with other associated gene/proteins. Results: The GG wild-type genotype was more prevailed in the disease group as compared to the control. Significant downregulation in ASS1 and NOS2 genes was observed. Bioinformatics analysis reveals the correlation between ASS1 polymorphism and HCC development appears to be linked with the EMT pathway and polyamine production. Furthermore, MSI significantly resided in the disease group. Results were analyzed statistically to calculate the significance of obtained results. Conclusion: Study concludes that the insight of HCC mechanism through population-specific genetic mutations and altered gene expression of ASS1 might be helpful in early diagnostic and therapeutic purposes.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 30 (7) , 587-596
Polymorphic Variants of ASS1 Gene Related to Arginine Metabolism and the Risk of HCC
Background: Hepatocellular carcinoma is a primary liver cancer and 6th most common cancer globally. Inefficient diagnostic strategies and the limited availability of treatments are the foremost reasons. Variable factors directly impact the disease burden, among them, molecular alterations have been found to play a significant role. In liver, argininosuccinate synthase-1 is a center of arginine metabolism and rate limiting enzyme of urea cycle. It also triggers multiple mechanisms that lead to HCC pathogenesis. Objectives: The aim of this study is to analyze the ASS1 gene expression, its polymorphic genotype and microsatellite instability among HCC patients from our Pakistani population. Method: Blood samples were collected from disease and healthy control individuals. Allele-Specific PCR was performed for SNP analysis. MSI of tri and tetra nucleotide repeats were analyzed by PCR. The differential expression of ASS1 gene was also investigated. Furthermore, the reactome database and STRING software were utilized for finding correlations between ASS1 gene with other associated gene/proteins. Results: The GG wild-type genotype was more prevailed in the disease group as compared to the control. Significant downregulation in ASS1 and NOS2 genes was observed. Bioinformatics analysis reveals the correlation between ASS1 polymorphism and HCC development appears to be linked with the EMT pathway and polyamine production. Furthermore, MSI significantly resided in the disease group. Results were analyzed statistically to calculate the significance of obtained results. Conclusion: Study concludes that the insight of HCC mechanism through population-specific genetic mutations and altered gene expression of ASS1 might be helpful in early diagnostic and therapeutic purposes.
- Open Access
- 6 February 2014
- Published by Wiley in International Journal of Proteomics
- Vol. 2014, 1-9
The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines
Cancer is a life threatening disorder effecting 11 million people worldwide annually. Among various types of cancers, Hepatocellular carcinoma (HCC) has a higher rate of mortality and is the fifth leading cause of cancer related deaths around the world. Many chemotherapeutic drugs have been used for the treatment of HCC with many side effects. These drugs are inhibitors of different cell regulatory pathways. Mevalonate (MVA) pathway is an important cellular cascade vital for cell growth. A variety of inhibitors of MVA pathway have been reported for their anticancerous activity. Bisphosphonates (BPs) are members of a family involved in the treatment of skeletal complications. In recent years, their anticancer potential has been highlighted. Current study focuses on exploring the effects of alendronate (ALN), a nitrogen containing BP, on hepatocellular carcinoma cell line using genomic and proteomics approach. Our results identified ten differentially expressed proteins, of which five were up regulated and five were down regulated in ALN treated cells. Furthermore, we also performed gene expression analysis in treated and control cell lines. The study may help in understanding the molecular mechanism involved in antitumor activity of ALN, identification of possible novel drug targets, and designing new therapeutic strategies for HCC.
- 6 February 2014
- Published by Wiley in International Journal of Proteomics
- Vol. 2014, 1-9
Open AccessThe Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines
Cancer is a life threatening disorder effecting 11 million people worldwide annually. Among various types of cancers, Hepatocellular carcinoma (HCC) has a higher rate of mortality and is the fifth leading cause of cancer related deaths around the world. Many chemotherapeutic drugs have been used for the treatment of HCC with many side effects. These drugs are inhibitors of different cell regulatory pathways. Mevalonate (MVA) pathway is an important cellular cascade vital for cell growth. A variety of inhibitors of MVA pathway have been reported for their anticancerous activity. Bisphosphonates (BPs) are members of a family involved in the treatment of skeletal complications. In recent years, their anticancer potential has been highlighted. Current study focuses on exploring the effects of alendronate (ALN), a nitrogen containing BP, on hepatocellular carcinoma cell line using genomic and proteomics approach. Our results identified ten differentially expressed proteins, of which five were up regulated and five were down regulated in ALN treated cells. Furthermore, we also performed gene expression analysis in treated and control cell lines. The study may help in understanding the molecular mechanism involved in antitumor activity of ALN, identification of possible novel drug targets, and designing new therapeutic strategies for HCC.